Nausea and vomiting are chemotherapy adverse events that influence breast cancer patient's quality of life. Antiemetic regimen as premedication was given to prevent those adverse events and need to be evaluated. This study aimed to present the effectiveness of antiemetic treatment among breast cancer patients in the inpatient unit, Rumah Sakit Umum Pusat Dr. Sardjito [Central Public Hospital Dr. Sardjito] Yogyakarta, Indonesia. A cohort study was used in this study during July 2008 to January 2009. Thirty-one breast cancer patients, who are receiving antiemetic therapy and having no disease that induced nausea and vomiting were involved, signed informed consent and had been followed by before-post chemotherapy. The data was gained from chemotherapy and antiemetic regimens, medical records, patient's interviews, and finally analyzed using descriptive, evaluative approach. This study presented that antiemetic treatment among breast cancer patient in the inpatient unit was 61.40 % ineffective reducing incidence of nausea vomiting events. The majority of cases of nausea and vomiting onset among patients were acute-delayed (56.2 %; 52.0 %), severity of nausea and vomiting laid mostly in the second level (54.54 %; 52.00 %), and appropriateness antiemetic treatment complied to NCCN guideline 2007 and ASCO guideline 2006 was only applied in low emetic risk of chemotherapy-induced nausea and vomiting. Antiemetic regimens that had been implemented need to be evaluated because of majority cases of nausea and vomiting were the acute-delayed type, level two of severity and inappropriateness of international guideline. This study should be followed with the future study of the evaluation of the effectiveness of another medication supported the patient in receiving chemotherapy.
Introduction
About 7 600 000 from 58 000 000 people died caused by cancer, and 70 % of them lived in low-middle income countries with minimum prevention, therapy availability, and accessibility. The number of death caused by cancer projected increasing by 11 400 000 Chemotherapy is selected as the main therapy for treated breast cancer [3, 4] . Nausea and vomiting are the adverse effects of chemotherapy that frequently reported and negatively affected patients, especially in their daily life, the quality of life of patients and the adherence to chemotherapy. Uncontrolled nausea vomiting would lead to the worsen patient's condition, decreased patient's appetite, poor nutritional status, dehydration, electrolyte disturbances and pneumonia [5] . To overcome it, patient in undergoing chemotherapy commonly used antiemetic as prophylaxis [6] .
Based on the data above, the treatment of nausea and vomiting among patients with breast cancer need to be evaluated especially the effectiveness of its therapy for supporting the quality life of patients. So, assessing the effectiveness of nausea and vomiting treatment is very important, to know the extent to which the management of these therapies successfully implemented and to see the treatment will bring great benefit to the patients or not.
Methods
This study aimed to present the effectiveness of antiemetic treatment among breast cancer patients in the inpatient unit, Rumah Sakit Umum Pusat -RSUP Dr. Sardjito (Central Public Hospital Dr. Sardjito) Yogyakarta, Indonesia. Central Public Hospital Dr.
Sardjito Yogyakarta was chosen as study location because it is one of referral hospital for cancer in Indonesia, especially in Central Java Province and D.I. Yogyakarta Province.
Breast cancer was in the second top rank of cases in this hospital from 2003 to 2004 [7] . All respondents were breast cancer patients who voluntarily recruited during July 2008 to January 2009 and met the inclusion criteria such as (i) receiving antiemetic therapy, (ii) having no disease that induced nausea and vomiting, (iii) signed informed consent, (iv) having completed medical records, chemotherapy protocols, and (v) having willingness to be interviewed. About 55 patients (110 cases) were obtained and signed informed consent, only 31 patients (57 cases) were enrolled with completed data.
This study used a cohort study with descriptive evaluation approach. The data was gained prospectively. The instruments of this study were semi-structured inter- incomplete data pre and post-chemotherapy due to inconsistence patient's treatment schedule. It made 26 patients who potential and having a willingness to join this study failed to be followed up. 
Results
Breast cancer patients received various chemotherapy regimens (low, moderate, and high emetic chemotherapy agents) in four or six cycles. All of them were women (100 %), with majority 50 yr to 59 yr (45.2 %). It was relevant with data from Canadian Cancer Statistics in 2007 [8] . Most of them were menopause (83.9 %) and in the advance stages of cancer (81.2 %). This fact appeared due to the delayed diagnosis of cancer. Mostly, the patient got anemia in the second cycle of their chemotherapy treatment (13.46 %).
This hematology complication affected the type and duration of therapy and malignant stages due to the decision having a blood transfusion. The family history of breast cancer patients have been traced, only five patients (16.13 %) showed that their mother or sister who died because of cancer. All of breast cancer patients experienced nausea, vomiting, and both of events. About 61.4 % patients still perceived nausea and/or vomiting, only 38.60 % were free from those events. See table 3. If we take a look in details, the cases of nausea-induced chemotherapy (33 cases) were higher than vomiting-induced chemotherapy (25 cases).
The severity levels of nausea and/or vomiting were presented mostly in second level (from 5 levels) for nausea (54.45 %) and vomiting (52.00 %).
The onset of nausea and vomiting were presented separately in 2 figures, Fig. 2 .
Patients who received high emetic risk of chemotherapy regimens experienced vomiting in several hours after chemotherapy in first day (acute). Low-moderate emetic risk extremely induced nausea and vomiting in the first day and followed more than 5 d (delayed).
The antiemetic, its relation of emetic risk level and chemotherapy regimens that had been chosen presented well in 
Discussion
Reducing the cases of nausea and/or vomiting after chemotherapy difficult to be attempted. Table 3 presented the number of cases and its categories. Those data were in line with Germany cancer center study, about 62.5 % nausea events had been recorded compared to the vomiting events which only shown about 26 % [9] . Acute onset, delayed onset or both events of nausea and vomiting appeared clearly. It showed that those events hardly avoided [10] . Patients who got chemotherapy regimens with high emetic risks (> 90 %) tended to experience nausea and vomiting rather than the combination of low-moderate risks (10 % to 30 %, 30 % to 90 %) and low risks regimens (10 % to 30 %). Table 5 showed that the patients who got high emetic chemotherapy regimens (AC and CE regimens) treated mostly with metoclopramide only (10 cases) which did not appropriate with the ASCO or NCCN Guideline [11] . Low dose metoclopramide stimulated gastric emptying, in high dose, metoclopramide worked to stop the stimulation to the brain which can cause nausea vomiting [5] . Blocking dopamine-2 was not only enough because of the complexity of emesis induced chemotherapy. They were undertreated and should receive a combination of antiemetic drug therapy to prevent nausea and/or vomiting. Dexamethasone, ranitidine, and diphenhydramine are needed to be added in the antiemetic regimens [11] .
Contrary, patients who received low risks chemotherapy regimens, T regimens, (10 cases) found over-treated. The patient got a combination of antiemetic premedication, metoclopramide, dexamethasone, and diphenhydramine. Only seven cases from 10 cases successfully reduced the level severity of nausea and vomiting events. This fact showed that antiemetic premedication that had been provided to the patients did not meet the therapeutic goals. The majority of antiemetic regimens provided in combination in order to increase the efficacy of drugs reduced the toxicity of antiemetic therapy and preventing the adverse effect of chemotherapy. Metoclopramide or Ondansetron combined with another Table 7 : Antiemetic regimens that had been received and its appropriateness to the ASCO guideline and NCCN guideline. properties of 5HT3 agents [2] . Ranitidine (22.9 %) frequently needed to be added in nausea vomiting therapy by reducing acid secretion. The cytotoxic agent could damage gastric mucus up to gastrointestinal tract -Diphenhydramine commonly used as an additional medication to reduce the side effect of metoclopramide, extrapyramidal symptom [11] .
Emetic Risk
All antiemetic regimens that had been provided to the breast cancer patient did not appropriate with NCCN and ASCO guideline. The aprepitant that had been recommended since 2003 was not available in Indonesia as the main reason [11, 12] .
Conclusions
Antiemetic regimens were ineffective because of several factors, such as cases of nausea and vomiting still dominants (64.91 %) with the type of onset acute-delayed, level two of severity, and inappropriateness with NCCN (2007) standard and ASCO (2006) standard.
This study finding will be useful for Central Public Hospital Dr. Sardjito to have better services to breast cancer patients who are dealing with nausea and vomiting during chemotherapy treatment.
